Cytochalasin B (Phomin) (Synonyms: NSC 107658, Phomin) |
| Catalog No.GC32890 |
Cytochalasin B (Phomin) es una micotoxina citopermeable, y está asilada de un hongo ascomiceto perteneciente al género Phoma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 14930-96-2
Sample solution is provided at 25 µL, 10mM.
Cytochalasin B (Phomin) es una micotoxina citopermeable, y está asilada de un hongo ascomiceto perteneciente al género Phoma[1-2]. Cytochalasin B es capaz de inhibir la formación de microfilamentos de actina a través de un efecto directo sobre la polimerización de la proteína citoesquelética. Al unirse al extremo de rápido crecimiento de la F-actina e interactuar con las proteínas de tapa, influye en la nucleación-alargamiento de los microfilamentos de actina[3-4].
Cytochalasin B (0.1-10 µM; 0-72 h) influyó en el metabolismo, la proliferación y la morfología de las hASCs de una manera dependiente de la dosis, en asociación con la desorganización progresiva de los microfilamentos de actina[5]. Cytochalasin B es capaz de inducir la fragmentación del DNA en varias líneas celulares[6]. Cytochalasin B (10-8-10-1M; 24-96 h) inhibió eficazmente la proliferación celular U251 de una manera dependiente de la dosis y el tiempo. Cytochalasin B aumentó la proporción de células en la fase G2/M de una manera dependiente así el ídice mitótico y disminuyendo los niveles de proteína CDC2 y cyclin B1 [7].
Cytochalasin B(Cytochalasins B se preparó en forma de suspensión en carboximetilcelulosa al 2% al 1% entre 20 (CMC/Tw); i.p.;10, 25, o 50 mg/kg; 8 días) dependeinte de la dosis aumenta la esperanza de vida de ratones Balb/c portadores de leucemias P388/ADR [8]. El tratamiento con Cytochalasin B(5 µg/ml Cytochalasin B; 30 min) de ovocitos de ratón durante la inyección intracitoplasmásica de espermatozoides (ICSI) aumenta la supervivencia embrionaria sin deterioro del desarrollo[9].
References:
[1]. Van Goietsenoven G, Mathieu V, et,al. In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. Planta Med. 2011 May;77(7):711-7. doi: 10.1055/s-0030-1250523. Epub 2010 Nov 5. PMID: 21058241.
[2]. Trendowski M. Using cytochalasins to improve current chemotherapeutic approaches. Anticancer Agents Med Chem. 2015;15(3):327-35. doi: 10.2174/1871520614666141016164335. PMID: 25322987; PMCID: PMC4485394.
[3]. MacLean-Fletcher S, Pollard TD. Mechanism of action of cytochalasin B on actin. Cell. 1980 Jun;20(2):329-41. doi: 10.1016/0092-8674(80)90619-4. PMID: 6893016.
[4]. Flanagan MD, Lin S. Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J Biol Chem. 1980 Feb 10;255(3):835-8. PMID: 7356663.
[5]. Bianconi E, Tassinari R, et,al. Cytochalasin B Modulates Nanomechanical Patterning and Fate in Human Adipose-Derived Stem Cells. Cells. 2022 May 12;11(10):1629. doi: 10.3390/cells11101629. PMID: 35626666; PMCID: PMC9139657.
[6]. Kolber MA, Broschat KO, et,al. Cytochalasin B induces cellular DNA fragmentation. FASEB J. 1990 Sep;4(12):3021-7. doi: 10.1096/fasebj.4.12.2394319. PMID: 2394319.
[7]. Tong ZG, Liu N, et,al. Cytochalasin B inhibits the proliferation of human glioma U251 cells through cell cycle arrest and apoptosis. Genet Mol Res. 2014 Dec 19;13(4):10811-22. doi: 10.4238/2014.December.19.2. PMID: 25526201.
[8]. Trendowski M, Mitchell JM, et,al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9. doi: 10.1007/s10637-014-0203-5. Epub 2015 Jan 7. PMID: 25563824; PMCID: PMC4387261.
[9].Hu LL, Shen XH, et,al. Cytochalasin B treatment of mouse oocytes during intracytoplasmic sperm injection (ICSI) increases embryo survival without impairment of development. Zygote. 2012 Nov;20(4):361-9. doi: 10.1017/S0967199411000438. Epub 2011 Aug 15. PMID: 21838963.
| Experimentos celulares [1]: | |
Líneas celulares | Células madre mesenquimales humanas (hMSCs) |
Método de preparación | Las células se cultivaron en presencia de Cytochalasin B o DMSO al 0.05%. |
Condiciones de reacción | 0.1-10 µM; 0-72 h |
Áreas de aplicación | Cytochalasin B influyó en el metabolismo, la proliferación y la morfología de los hMSCs de una manera dependeinte de la dosis. |
| Experimentos con animales [2]: | |
Modelos animales | Ratones Balb/c (que llevan leucemias P388/ADR) |
Método de preparación | A los ratones (con leucemias P388/ADR) se les administró Cytochalasin B los días 1-8. |
Forma de dosificación | Cytochalasins B se prepararon en forma de suspensión en carboximatilcelulosa al 2% al 1% entre 20 (CMC/Tw); i.p.;10, 25, o 50 mg/kg; 8 días |
Áreas de aplicación | Cytochalasin B aumenta de forma dependiente de la dosis la esperanza de vida de los ratones Balb/c portadores de leucemias P388/ADR. |
References: | |
| Cas No. | 14930-96-2 | SDF | |
| Sinónimos | NSC 107658, Phomin | ||
| Canonical SMILES | O=C1N[C@@H](CC2=CC=CC=C2)[C@@]3([H])[C@]14[C@](/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(O4)=O)([H])[C@H](O)C([C@H]3C)=C | ||
| Formula | C29H37NO5 | M.Wt | 479.61 |
| Solubility | DMF: 30 mg/ml DMF:PBS (pH 7.2) (1:20): 0.05 mg/ml DMSO: 20 mg/ml Ethanol: 20 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.085 mL | 10.4251 mL | 20.8503 mL |
| 5 mM | 417 μL | 2.085 mL | 4.1701 mL |
| 10 mM | 208.5 μL | 1.0425 mL | 2.085 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *